Rick Simpson Oil (RSO) in Bouvet Island: The Complete Guide by OilWell Cannabis

Introduction: Cannabis and Isolation in the World’s Most Remote Island

Bouvet Island is the most isolated place on Earth. Located in the South Atlantic Ocean, this uninhabited volcanic island sits approximately 1,600 kilometers from the nearest landmass—Queen Maud Land in Antarctica. With no permanent residents, no airports, and no ports, Bouvet Island exists in a state of profound solitude. The island is a Norwegian dependency, governed under the Antarctic Treaty System, and is primarily visited by scientific expeditions studying climate change, geology, and wildlife.

For those rare individuals who find themselves on Bouvet Island—whether researchers, support staff, or adventurers—the challenges of isolation are immense. Extreme weather, limited medical resources, and the psychological toll of prolonged solitude create unique health and wellness needs. In such an environment, access to natural, supportive therapies becomes not just a preference but a necessity.

This is where Rick Simpson Oil (RSO) and OilWell Cannabis enter the conversation. While Bouvet Island itself has no cannabis culture, no dispensaries, and no local production, the global accessibility of high-quality, lab-tested RSO offers a potential solution for those who seek natural support for pain, sleep, anxiety, and overall well-being—even in the world’s most remote locations.

In this guide, we explore the history of RSO, the science behind its potential benefits, and how OilWell Cannabis has evolved the traditional RSO formula to create a modern, evidence-informed product that can be shipped internationally—including to Bouvet Island. We’ll also address the practical considerations of using RSO in an isolated environment, the legal framework that makes this possible, and how to integrate RSO into a holistic wellness routine when conventional medical resources are limited.

The Legacy of Rick Simpson: From Nova Scotia to the World

Who Was Rick Simpson?

Rick Simpson was a Canadian power engineer and maintenance worker born in 1949 in Amherst, Nova Scotia. He was not a doctor, scientist, or medical professional, but his personal journey with cannabis would later inspire a global movement. Simpson’s path into cannabis advocacy began with personal suffering. In 1997, while working at a hospital in Moncton, New Brunswick, he fell from scaffolding and sustained a serious head injury. The aftermath included persistent tinnitus, dizziness, and post-concussion symptoms that conventional medicine struggled to address. Simpson reported that the medications prescribed to him either failed to help or made his condition worse. When he asked his physician about cannabis as an alternative, the request was refused.

Simpson’s interest in cannabis deepened after he learned about a 1974 study funded by the National Institute of Health (NIH) and conducted at the Medical College of Virginia. The study found that THC (tetrahydrocannabinol) slowed or shrank tumors in mice. Though the study was originally intended to demonstrate harm, its findings were never replicated in controlled human trials. Nevertheless, it became a foundational reference point in Simpson’s later advocacy.

The Turning Point: Simpson’s Skin Cancer Story

The pivotal moment in Simpson’s story came in 2003, when he reported that three bumps on his arm were diagnosed as basal cell carcinoma. Rather than pursuing conventional treatment, Simpson applied concentrated cannabis oil directly to the lesions, covered them with bandages, and waited. According to his account, the bumps disappeared within four days. No independent medical verification of this outcome was ever published, and no biopsy confirmation or clinical follow-up was documented in peer-reviewed sources. However, this personal experience became the origin story of Rick Simpson Oil (RSO) and the foundation of everything that followed.

It’s important to note that Simpson’s account is personal testimony, not medical evidence. The absence of clinical documentation means these events cannot be evaluated as medical proof. However, they are historically significant as the catalyst for a global movement around concentrated cannabis oil. Simpson’s story resonates with many people who feel let down by conventional medicine, particularly those facing chronic or life-threatening conditions. This is especially relevant in isolated environments like Bouvet Island, where medical resources are limited, and individuals may be forced to seek alternative solutions.

The Crusade: Spreading the Oil

After his 2003 experience, Simpson committed himself to producing and distributing concentrated cannabis oil. Operating from his property in Maccan, Nova Scotia, he began making the oil in large quantities and giving it away for free to cancer patients and others in his community. He charged nothing. By his own account, he helped dozens of people with conditions including cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, insomnia, and more.

Simpson’s story reached a global audience through the 2005 documentary Run From The Cure, directed by Christian Laurette. The film documented Simpson’s claims, featured testimonials from people he had treated, and framed his work as a grassroots challenge to pharmaceutical and governmental interests. The documentary was distributed freely online and became one of the most widely shared cannabis advocacy films of its era. For many people, Run From The Cure was their introduction to the concept of concentrated cannabis oil as medicine.

Simpson’s advocacy brought him into direct conflict with Canadian law. The Royal Canadian Mounted Police (RCMP) raided his property in 2005 and again in 2009, seizing plants and equipment. He was charged with cannabis cultivation, possession, and trafficking. Despite community support and public attention, he was eventually forced to leave Canada and relocated to Europe, where he continued his advocacy from abroad.

The Traditional RSO Protocol: Simpson’s 60-Gram, 90-Day Regimen

Simpson’s core treatment recommendation was a structured oral protocol designed to deliver a total of 60 grams (approximately 60 mL) of concentrated cannabis oil over roughly 90 days. He described this as a cancer treatment protocol, though he also recommended it for numerous other conditions. Below is a detailed breakdown of the protocol as Simpson described it:

Goal

Consume 60 grams of concentrated, high-THC cannabis oil over approximately 90 days. Simpson considered this the minimum amount necessary for a serious cancer treatment course.

Titration Schedule

• Week 1: Begin with a dose approximately the size of half a grain of dry rice—roughly 10 to 15 milligrams of oil—taken three times per day (morning, afternoon, and before bed). Total daily intake: approximately 30 to 45 milligrams. Simpson emphasized starting with very small doses to allow the body to adjust to the psychoactive effects of THC.
• Weeks 2 through 5: Double the dose approximately every four days. The purpose of the slow ramp-up was to build THC tolerance gradually and minimize disruption from psychoactive effects. By the end of this period—roughly four to five weeks in—the target was to reach approximately 1 gram (1,000 milligrams) of oil per day, divided into three roughly equal doses.
• Weeks 5 through 12: Maintain the full dose of approximately 1 gram per day, divided into three doses of roughly 333 milligrams each, and continue until the full 60 grams have been consumed. At this dosing level, the remaining 50-plus grams of oil would be consumed over the final seven to eight weeks.

Administration Methods

• Primary method—oral: Simpson recommended placing the dose directly under the tongue (sublingual) or swallowing it. He considered oral ingestion the most important route for systemic absorption and the primary method for internal cancers and other systemic conditions.
• Secondary method—topical: For skin cancers and external lesions, Simpson recommended applying the oil directly to the affected area, covering it with a bandage, and changing the bandage every three to four days. He combined topical application with oral dosing for skin cancers.
• Not recommended as primary—inhalation: Simpson did not recommend smoking or vaporizing the oil as a primary treatment method. He acknowledged inhalation for immediate symptom relief (pain, nausea) but maintained that the oral route was necessary for the sustained, high-dose exposure he considered therapeutically essential.

Tolerance and Psychoactive Effects

• Simpson maintained that patients would develop significant tolerance to the psychoactive effects of THC within approximately three to four weeks of consistent dosing at escalating levels.
• He considered the euphoric, sedating, or disorienting effects a minor and temporary side effect and strongly urged patients not to let the “high” discourage them from continuing the protocol.
• He recommended that patients take their initial doses at night or before bed to sleep through the most intense psychoactive effects during the early titration phase.
• Simpson also recommended that patients avoid driving or operating machinery during the titration period and that they inform family members about what to expect.

Post-Protocol Maintenance

• After completing the full 60-gram course, Simpson recommended a maintenance dose of approximately 1 to 2 grams of oil per month, taken indefinitely.
• He considered this ongoing low-dose maintenance important for long-term health and cancer prevention.

Dietary and Lifestyle Recommendations

• Simpson also advocated for dietary changes alongside the oil protocol, including reducing sugar intake, avoiding processed foods, and improving overall nutrition. However, he was not specific or systematic about dietary protocols compared to his highly detailed oil protocol.

Important Context for Evaluating This Protocol

This protocol was designed by one person based on his personal experience and anecdotal observations. It was not developed through clinical trials, dose-finding studies, pharmacokinetic modeling, or any formal research process. Several critical points apply:

• No controlled trial validation: There are no published randomized controlled trials, cohort studies, or even well-documented case series evaluating this specific 60-gram/90-day protocol for any cancer type or any other condition.
• Assumes crude, unstandardized material: The 60-gram quantity assumes a single-strain, THC-dominant extract with no standardized potency. Actual THC content per gram of traditional RSO varied widely depending on the starting plant material and extraction technique.
• Very high THC exposure: At the peak dosing phase, patients were consuming roughly 1 gram of high-THC oil per day. Assuming traditional RSO contained 60 to 90 percent THC, this translates to approximately 600 to 900 milligrams of delta-9 THC per day—a dose far exceeding anything studied in controlled clinical settings. For context, the FDA-approved synthetic THC drug dronabinol is typically dosed at 2.5 to 20 milligrams per day.
• Real risks at these doses: Consuming 600 to 900 milligrams of THC daily carries serious risks, including severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, and cannabis use disorder. These risks are well-documented in the scientific literature.
• Oncology context: Patients with active cancer are often medically complex. Using unregulated, unstandardized cannabis oil as a primary cancer treatment—potentially in place of proven therapies—introduces harm that extends beyond the oil itself.

For individuals in isolated environments like Bouvet Island, where medical oversight is limited, the risks associated with Simpson’s protocol are even more pronounced. The lack of standardized dosing, the high THC exposure, and the absence of clinical validation make this protocol unsuitable for unsupervised use.

What Is Traditional Rick Simpson Oil?

Traditional RSO refers to the specific type of concentrated cannabis oil that Simpson made and advocated for. It was defined not by lab specifications or regulatory standards but by his method and materials. Below is a description of the product as Simpson produced it:

Source Material

Simpson used high-THC, indica-dominant cannabis strains. He specifically favored heavy, sedating indica genetics and generally recommended against sativa-dominant strains for cancer treatment, believing that indica strains produced better therapeutic outcomes. He grew his own cannabis or sourced it from growers he trusted. There was no strain standardization—the starting material varied by availability and growing season.

Extraction Solvent

Simpson originally used naphtha—a petroleum-based solvent commercially available as lighter fluid, Varsol, or similar products. He later also endorsed 99 percent isopropyl alcohol as an acceptable alternative. He explicitly warned against using other solvents, including butane or acetone, due to safety and purity concerns. Neither naphtha nor isopropyl alcohol is a food-grade solvent, which is a significant safety issue.

Extraction Process

1. Dry or semi-dry cannabis plant material was placed in a container (typically a bucket).
2. The material was covered with solvent and agitated or stirred for several minutes to dissolve cannabinoids and other fat-soluble compounds from the plant.
3. The solvent was poured off through a filter, typically cheesecloth or a similar mesh material, into a separate collection vessel.
4. The process was repeated a second time with fresh solvent on the same plant material to extract remaining cannabinoids.
5. The combined solvent washes—now a dark, cannabinoid-rich liquid—were placed in a rice cooker or similar open-vessel heating device.
6. The solvent was evaporated at relatively low heat. Simpson recommended a rice cooker specifically because it maintains a temperature range that evaporates the solvent without exceeding the point at which cannabinoids degrade significantly. However, this temperature was still high enough to decarboxylate THCa into THC and to destroy most volatile terpenes.
7. As the solvent evaporated, a thick, dark oil remained at the bottom of the vessel.
8. The final oil was transferred into oral syringes for storage and dosing.

Appearance and Physical Characteristics

Traditional RSO was an extremely dark—nearly black—thick, viscous, tar-like oil. It had a strong cannabis odor and could carry a faint solvent-residual smell depending on how thoroughly the solvent was purged. The consistency was sticky and difficult to handle at room temperature but became more fluid when warmed slightly.

Cannabinoid Profile

• Primarily decarboxylated delta-9 THC: The heat involved in solvent evaporation converted essentially all THCa in the extract into delta-9 THC. Traditional RSO was therefore an activated, THC-dominant product.
• Naturally occurring minor cannabinoids: Whatever CBD, CBN, CBC, CBG, and other minor cannabinoids the source strain contained were present at their natural ratios, but these were not controlled, measured, or targeted.
• No ratio control: There was no ability to adjust or standardize specific cannabinoid ratios. The profile was entirely determined by the genetics and growing conditions of the source plant.
• Estimated THC content: Depending on starting material, traditional RSO likely ranged from approximately 60 to 90 percent total THC by weight, though this was never lab-verified in the traditional production context.

Terpene Content

Minimal to none. The combination of solvent extraction (which dissolves terpenes into the solvent along with cannabinoids) and the subsequent high-heat evaporation process (which volatilizes terpenes at temperatures well below cannabinoid degradation thresholds) meant that traditional RSO was effectively stripped of its terpene content. This is a significant distinction from modern formulations that deliberately preserve or reintroduce terpenes.

Standardization and Testing

None. Every batch of traditional RSO was different because it depended entirely on the starting plant material, growing conditions, solvent purity, extraction technique, evaporation temperature and duration, and the individual maker’s process. Simpson operated before cannabis legalization and the standardized lab-testing infrastructure that came with it. There was no Certificate of Analysis (COA), no cannabinoid quantification, and no contaminant screening.

Residual Solvent Risk

This is one of the most significant safety concerns with traditional RSO production. Naphtha and isopropyl alcohol are not food-grade solvents. Naphtha in particular is a complex mixture of petroleum hydrocarbons that may contain benzene, toluene, and other compounds classified as toxic or carcinogenic. Incomplete solvent purging—difficult to verify without lab testing—leaves potentially harmful residues in the finished oil. Modern extraction methods use food-grade ethanol or supercritical CO₂ to address this problem.

Simpson’s Claims vs. the Evidence Record

Rick Simpson made expansive therapeutic claims about his oil. He stated that RSO could cure cancer—including terminal cases—and that it was effective against diabetes, chronic pain, infections, glaucoma, arthritis, depression, insomnia, multiple sclerosis, and numerous other conditions. He was adamant, consistent, and public about these claims throughout his advocacy career.

It is important to evaluate these claims against the actual evidence base, using the same standards applied throughout this document.

What Simpson Was Not

Simpson was not a scientist, physician, pharmacologist, or researcher. He had no formal training in medicine, oncology, pharmacology, or clinical research methodology. He never designed, conducted, funded, or published a clinical trial. He never submitted his results to peer review. His entire evidence base consisted of personal experience, self-reported patient outcomes, and testimonials gathered informally—with no controls, no independent verification, no imaging confirmation, no long-term follow-up, and no blinding.

What the Preclinical Literature Shows

The preclinical cannabinoid-cancer literature does exist, and it is scientifically interesting:

• In vitro studies have demonstrated that THC and CBD can induce apoptosis (programmed cell death), inhibit proliferation, and reduce angiogenesis (blood vessel formation that feeds tumors) in certain cancer cell lines.
• Animal model studies have shown some tumor-growth inhibition in mice and rats treated with cannabinoids.
• These findings have generated legitimate scientific interest and ongoing research.

What the Preclinical Literature Does Not Show

• These findings have not translated into proven human cancer cures. The gap between in vitro or animal results and human clinical outcomes is vast and well-documented across all of oncology research.
• No human clinical trial has demonstrated that RSO or any cannabis oil preparation cures cancer.
• Several small human trials of cannabinoids in cancer contexts (particularly glioblastoma) have been conducted, but they have been exploratory, small, and have not produced the kind of results that would support cancer-cure claims.

Institutional Positions

• The U.S. National Cancer Institute (NCI) acknowledges that cannabinoids have been studied for potential anticancer effects in laboratory and animal models but does not endorse cannabis or cannabis oil as a cancer treatment.
• The U.S. Food and Drug Administration (FDA) has not approved any cannabis plant product for the treatment of cancer. The only FDA-approved cannabinoid-related products are for other specific indications: Epidiolex (CBD) for certain seizure disorders and dronabinol/nabilone (synthetic THC analogues) for chemotherapy-related nausea and AIDS-related wasting.
• Health Canada has never approved RSO or cannabis oil as a cancer cure.
• The National Center for Complementary and Integrative Health (NCCIH) explicitly states that the strongest cannabinoid evidence is for rare epilepsies, chemotherapy-related nausea and vomiting, and appetite-related indications in HIV/AIDS—not for cancer cure.

What Simpson Got Right

Simpson drew attention to cannabinoids as a serious area of biomedical research at a time when most of the world was ignoring or actively suppressing that conversation. His advocacy—however scientifically imprecise—helped create the political, cultural, and social conditions for the legal cannabis industry and the cannabinoid research infrastructure that exists today. He was among the first to bring concentrated cannabis oil to widespread public awareness, and the term “RSO” itself remains the most recognized name for full-spectrum cannabis extract in the consumer vocabulary.

What He Overstated

The leap from preclinical signals to cancer cure was not supported by human evidence when Simpson made it, and it is not supported now. Encouraging patients—particularly cancer patients—to rely on RSO as a primary treatment in place of proven oncologic therapies (surgery, radiation, chemotherapy, immunotherapy) carries genuine harm potential. Delayed or foregone treatment for treatable cancers is a documented concern in the alternative-medicine literature.

For individuals in isolated environments like Bouvet Island, where access to conventional cancer treatments is nonexistent, the stakes are even higher. While RSO may offer supportive benefits for symptom management, it should never be considered a replacement for proven medical interventions when they are available.

The Evolution of RSO: From Traditional to Modern Formulations

The term “RSO” is now used broadly—and often loosely—across the legal cannabis industry. Many products labeled as RSO bear little resemblance to what Simpson originally made. In dispensaries today, RSO can refer to almost any full-spectrum cannabis extract sold in a syringe format, regardless of extraction method, cannabinoid profile, terpene content, or intended use. The term has become generic.

Simpson himself was critical of commercial products that used the RSO name while departing significantly from his original method and philosophy. He publicly stated that many products sold as RSO did not meet his standards and that the commercialization of cannabis oil contradicted his original intent. Simpson’s model was explicitly anti-commercial—he gave the oil away for free and urged others to make their own rather than buy from companies.

This philosophical tension is worth acknowledging. Simpson believed in a do-it-yourself, free-access model in which anyone could grow cannabis, extract the oil, and treat themselves or their loved ones without corporate or governmental intermediaries. The modern cannabis industry has done something very different: it has commercialized, standardized, and regulated what Simpson distributed for free. Whether that evolution represents an improvement (through quality control, lab testing, and dosing precision) or a betrayal (through profit extraction and regulatory gatekeeping) depends on one’s perspective.

What is not in dispute is that modern RSO has evolved substantially from its origins, and those changes are directly relevant to the formulas in this document.

Traditional RSO vs. Modern Formulated RSO: A Comparison

The following table summarizes the key differences between traditional RSO as Simpson defined it and the modern formulated approach used in OilWell’s products:

Dimension	Traditional RSO	OilWell Formulated RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by high-heat process	Live terpenes at 5% with defined seven-terpene profile
Standardization	None—every batch different	Lab-tested with specific mg/mL targets
Lab testing	Not available or performed	Full panel testing (potency, terpenes, pesticides, heavy metals, residual solvents, microbial contaminants)
Residual solvents	Significant risk with naphtha	Controlled and tested
Dosing precision	Approximate, syringe-based	Measured per mL with known cannabinoid content (553 mg/mL)
Product formats	Single thick oil only	Sublingual oil and vape cartridge with format-specific formulas
THCa preservation	No—fully decarboxylated by heat	Yes—THCa included as a separate ingredient at 1,500 mg
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted

Why OilWell’s Formulas Diverge from Traditional RSO

OilWell’s formulations are not traditional RSO. They are informed by the RSO tradition but depart from it in several deliberate, evidence-motivated ways:

1. Multi-cannabinoid approach: Traditional RSO relied on whatever single strain the maker grew or sourced. OilWell’s formulas intentionally include seven cannabinoids—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC—because the entourage-effect literature suggests potential benefit from cannabinoid diversity, even though robust clinical proof of whole-formula synergy remains limited.

2. Terpene preservation and addition: Traditional RSO had essentially no terpene content due to solvent and heat destruction. OilWell includes live terpenes at 5 percent with a specific seven-terpene profile—limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene—because terpene bioactivity is plausible and supported at the preclinical level, even if human clinical confirmation for cannabis-specific terpene effects is still developing.

3. THCa as a separate ingredient: Traditional RSO fully decarboxylated everything, converting all THCa into delta-9 THC. OilWell’s sublingual formula includes THCa at 1,500 mg as a distinct ingredient, preserving the acidic precursor because the THCa literature suggests potentially relevant non-psychoactive bioactivity that is lost when THCa converts to THC.

4. Reduced delta-9 THC dominance: Traditional RSO was overwhelmingly delta-9 THC—often 60 to 90 percent of total cannabinoid content. OilWell’s sublingual formula uses delta-9 THC at only 90 mg while incorporating delta-8 THC at 6,000 mg and distributing the remaining cannabinoid content across CBD (4,500 mg), CBG (3,000 mg), CBN (750 mg), and CBC (750 mg). This reflects the broader cannabinoid research landscape rather than a single-compound dominance model.

5. Product format innovation: Simpson envisioned only one format: an oral oil administered from a syringe. OilWell offers both a 30 mL sublingual oil and a 1-gram vape cartridge, each with its own format-specific formulation acknowledging that different delivery routes have different pharmacokinetic profiles.

Solvent Safety and Extraction Evolution

Traditional RSO production used naphtha or isopropyl alcohol—neither of which is food-grade. Naphtha is a complex petroleum hydrocarbon mixture that may contain benzene, toluene, xylene, and other compounds with established toxicity. Isopropyl alcohol, while cleaner than naphtha, is also not intended for internal consumption. Incomplete solvent purging—difficult to verify without analytical chemistry equipment—leaves potentially harmful residues in the finished oil.

Modern cannabis extraction overwhelmingly uses food-grade ethanol or supercritical carbon dioxide (CO₂). These methods allow for much more complete solvent removal, and the finished products can be tested for residual solvents using validated analytical methods such as headspace gas chromatography. This is one of the most straightforward improvements that the modern regulated cannabis industry has made over the traditional RSO production model.

For individuals in isolated environments like Bouvet Island, where access to medical care is limited, the importance of solvent-free production cannot be overstated. The risk of residual solvents in traditional RSO is a significant safety concern that modern formulations like OilWell’s have addressed.

The Decarboxylation Choice: Patient-Controlled Potency

Traditional RSO was fully decarboxylated. The heat involved in evaporating solvent from the rice cooker—typically sustained at or near the boiling point of the solvent—was sufficient to convert essentially all THCa in the extract into delta-9 THC. This conversion is thermodynamically favored and proceeds readily at these temperatures over the durations involved in solvent evaporation.

As a result, the acidic cannabinoids that exist abundantly in raw cannabis plant material—including THCa, CBDa, CBGa, and others—were lost as distinct compounds in traditional RSO. The finished oil was a decarboxylated, activated product dominated by neutral (non-acidic) cannabinoids.

OilWell’s sublingual formula deliberately preserves THCa at 1,500 mg as a separate ingredient. This is an intentional formulation choice informed by the THCa evidence profile, which notes that THCa itself does not produce the psychoactive effects associated with THC but that its interpretation depends on route, temperature, processing, and storage—because THCa can convert to THC under heating or over time.

Three Distinct Usage Options for the Customer

1. Raw, no heat: All 1,500 milligrams stays as THCa—completely non-psychoactive. The THCa evidence profile describes potential anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism. This option is compatible with work, driving, and daytime use with zero psychoactive impairment.

2. Fully activated, home decarboxylation: Heating the oil at 260°F (125°C) for 45 to 60 minutes in an oven-safe glass container converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams of delta-9 THC already in the formula, this yields approximately 1,405 milligrams of total delta-9 THC. Combined with 6,000 milligrams of delta-8 THC, the activated product achieves psychoactive potency comparable to traditional high-THC RSO—100 percent legally, because decarboxylation occurs at the customer’s discretion after purchase. The customer may also transfer a controlled portion of the oil from the original bottle into a second empty oven-safe glass container, decarboxylating only what they intend to use and preserving the remainder in its raw THCa form.

3. Vape, auto-decarboxylation: The RSO Vape Cartridge vaporizes at 400 to 450°F, which instantly converts THCa to delta-9 THC with each inhalation. Every puff delivers freshly decarboxylated cannabinoids. This is the fastest-onset RSO delivery method available.

The conversion chemistry: THCa has a molecular weight of 358.47 g/mol. The conversion ratio is approximately 1 milligram THCa = 0.877 milligrams delta-9 THC after decarboxylation, reflecting the loss of a CO₂ molecule during the reaction.

This design puts the potency decision entirely in the customer’s hands—aligning with Rick Simpson’s principle that patients should control their own medicine, but implementing that principle through actual product chemistry rather than a one-size-fits-all approach.

Terpene Loss in Traditional RSO

Terpenes are volatile aromatic compounds with relatively low boiling points. Most cannabis terpenes begin to volatilize at temperatures between 21 and 157 degrees Celsius, with many of the most abundant terpenes—including myrcene, limonene, and pinene—having boiling points below 180 degrees Celsius. The traditional RSO production process destroyed terpenes in two ways: first, by dissolving them into the solvent wash along with cannabinoids; and second, by evaporating them off during the high-heat solvent-removal phase.

This meant that traditional RSO was essentially a cannabinoid-only product, despite being derived from a terpene-rich plant. Whatever aromatic, flavoring, or potentially bioactive terpene compounds the source cannabis contained were lost in production.

OilWell’s formulas specify live terpenes at 5 percent with a defined seven-terpene profile: limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene. Each of these terpenes has its own evidence profile, and the entourage-effect literature provides the theoretical framework for why preserving and including terpenes alongside cannabinoids may matter pharmacologically, even though robust human clinical proof of cannabis-specific entourage effects remains limited.

Evidence Standards Then and Now

Rick Simpson operated in a pre-legalization, pre-lab-testing era. When he began making and distributing oil in the early 2000s, cannabis was illegal in Canada and throughout most of the world. There was no regulatory framework for cannabis products, no standardized testing infrastructure, no legal pathway for clinical research on cannabis oil protocols, and no peer-reviewed journals dedicated to cannabis therapeutics. The cannabis underground was the only access point, and personal experience was the primary evidence currency.

Simpson’s methods reflected the constraints of that era. His evidence was anecdotal. His production was unstandardized. His claims were untested in any formal sense.

This document takes a fundamentally different approach. The GENERAL KNOWLEDGE section applies a formal evidence hierarchy: human clinical evidence first, then systematic reviews and meta-analyses, then institutional summaries, then preclinical and mechanistic literature. Every compound-level claim is tied to specific peer-reviewed sources with evidence strength clearly labeled. The intent is to honor the historical origin of RSO while committing to the standards of modern cannabinoid science. Where Simpson relied on personal testimony, this document relies on published literature and institutional sources.

Simpson’s Protocol vs. Modern Dosing Considerations

Simpson’s 60-gram/90-day protocol was designed around a crude, single-strain, THC-dominant extract with no standardized potency. A direct comparison between Simpson’s dosing recommendations and dosing with a modern, standardized, multi-cannabinoid formulation is not straightforward—the products are fundamentally different.

Several key differences illustrate why:

• Cannabinoid concentration: OilWell’s sublingual formula delivers 553 mg of total active cannabinoids per mL across seven defined compounds. Traditional RSO potency was unknown and variable.
• Cannabinoid ratios: Simpson’s oil was approximately 60 to 90 percent delta-9 THC. OilWell’s formula distributes 16,590 mg of total cannabinoids across CBD (4,500 mg), CBG (3,000 mg), delta-8 THC (6,000 mg), THCa (1,500 mg), delta-9 THC (90 mg), CBN (750 mg), and CBC (750 mg)—a completely different pharmacologic profile.
• Terpene presence: Simpson’s oil had no terpenes. OilWell’s formula includes live terpenes at 5 percent, which may influence absorption, effect, and tolerability.
• Delta-9 THC exposure: Simpson’s protocol at peak dosing delivered approximately 600 to 900 mg of delta-9 THC per day. OilWell’s sublingual formula contains only 90 mg of delta-9 THC in the entire 30 mL bottle (3 mg per mL), making the per-dose delta-9 THC exposure dramatically lower.

Future dosing guidance for OilWell products should be developed independently of Simpson’s protocol, informed by the per-compound evidence in the GENERAL KNOWLEDGE section and by responsible titration principles that account for the safety profile of each individual cannabinoid.

The Science Behind OilWell’s RSO Formula

OilWell’s RSO is not just a modernized version of traditional RSO—it is a completely reimagined formulation grounded in scientific evidence. Below, we explore the science behind each cannabinoid and terpene in OilWell’s formula, as well as the rationale for their inclusion.

Cannabinoids in OilWell’s RSO

CBD (Cannabidiol) – 4,500 mg

• Evidence profile: Strongest human evidence in the current formula set, especially when CBD is studied as a purified product rather than as a loose wellness ingredient.
• What is best supported: Purified CBD has the most credible human evidence in seizure disorders, particularly for rare forms of epilepsy such as Dravet syndrome and Lennox-Gastaut syndrome. This is the clearest major-example indication acknowledged by institutional and peer-reviewed literature.
• Anxiety research: A 2024 systematic review and meta-analysis covering 316 participants across eight eligible articles reported a statistically significant anxiolytic signal, but the authors also stressed that the clinical sample remains limited and that more trials are needed before broad conclusions are justified.
• Pain research: A 2024 systematic review of clinical and preclinical CBD monotherapy studies concluded that the pain literature is promising but heterogeneous, with trial quality and consistency still limiting confidence in broad analgesic claims.
• Sleep research: A 2023 insomnia review found that the literature remains methodologically weak, with many studies relying on nonvalidated subjective measures and relatively few objective sleep assessments.
• Safety and interaction concerns: A 2023 systematic review and meta-analysis found a real signal for liver enzyme elevation and possible drug-induced liver injury in some CBD contexts, which is especially relevant for concentrated oral products and polypharmacy settings. NCCIH separately flags diarrhea, sleepiness, appetite change, mood effects, liver-function abnormalities, and drug-drug interactions as important considerations.
• Bottom line: CBD is the most evidence-developed nonintoxicating cannabinoid in this formula, but even here, strong evidence is concentrated in a few specific indications rather than in the broad, generalized wellness claims often seen in marketing.

CBG (Cannabigerol) – 3,000 mg

• Evidence profile: Mostly review-level and preclinical; human evidence remains sparse.
• Pharmacology: CBG is the biosynthetic precursor to several major cannabinoids and appears pharmacologically distinct from both THC and CBD. Review literature describes interactions spanning cannabinoid receptors as well as alpha-2 adrenoceptors and 5-HT1A-related signaling, which makes it mechanistically interesting but not yet clinically established.
• Potential research areas: Published reviews discuss possible relevance to neurologic disorders, inflammatory bowel disease, and antibacterial activity, but these are primarily pharmacology-led hypotheses or preclinical findings rather than mature human therapeutic conclusions.
• Caution: One of the key points from the 2021 pharmacology review is that CBG is already being sold commercially while the evidence base remains thin, which means claims frequently outrun the science.
• Bottom line: CBG is a serious research topic, but at present it should be described as a promising minor cannabinoid with limited clinical validation rather than as a proven therapeutic cannabinoid.

Delta-8 THC – 6,000 mg

• Evidence profile: Pharmacologically relevant, psychoactive, and much less clinically characterized than delta-9 THC.
• Comparative pharmacology: A 2022 review concluded that delta-8 THC and delta-9 THC have broadly similar pharmacokinetic and pharmacodynamic behavior. Delta-8 THC is a partial CB1 agonist with cannabimimetic activity in animals and humans, but it appears less potent than delta-9 THC, likely in part because of weaker CB1 affinity.
• Public-health literature: A 2023 scoping review found that much of the delta-8 evidence base is still dominated by animal studies, product chemistry, use reports, and public-health concerns rather than strong modern human trials. The same review also noted reports of adverse consequences and emphasized regulatory and product-quality concerns.
• Manufacturing context: The recent chemistry and pharmacology review reinforces that commercial delta-8 interest is tied to greater stability and easier synthesis relative to naturally scarce plant levels, which is part of why product-byproduct and lab-testing questions matter.
• Bottom line: Delta-8 THC should be treated as a psychoactive THC analogue with real pharmacologic activity, incomplete human safety characterization, and more manufacturing-quality uncertainty than many consumers realize.

THCa (Tetrahydrocannabinolic Acid) – 1,500 mg

• Evidence profile: Important chemically and formulation-wise, but still low on direct human therapeutic evidence.
• What it is: THCa is the acidic, non-psychoactive precursor to delta-9 THC. It is not itself delta-9 THC. This distinction is legally significant: THCa is Farm Bill compliant at the point of sale because it has not been converted to delta-9 THC.
• Psychoactivity: The major review source stresses that THCa itself does not produce the psychoactive effects associated with THC in humans, but the distinction only holds if the molecule stays in its acidic form and is not substantially decarboxylated.
• Research status: In vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, and antineoplastic possibilities, but these are not equivalent to established human outcomes.
• Bottom line: THCa is best understood as a highly relevant precursor molecule whose interpretation depends heavily on route, temperature, processing, and storage. Any claim about THCa needs to account for possible conversion into THC.

Delta-9 THC – 90 mg

• Evidence profile: Strongest human evidence of the psychoactive cannabinoids listed here, but also the clearest adverse-effect burden.
• What is institutionally best supported: NCCIH identifies THC-containing cannabinoid medicines as relevant to chemotherapy-related nausea and vomiting, appetite and weight loss in HIV/AIDS, and some multiple-sclerosis- and pain-related outcomes, while still stressing that many other uses remain uncertain or early-stage.
• Pain evidence: A 2022 systematic review of cannabis-based products for chronic pain found that products with high THC content or roughly comparable THC:CBD ratios may provide short-term pain benefit, but they also increased dizziness, sedation, nausea, and treatment discontinuation due to adverse events.
• Pharmacokinetics and onset: Classic pharmacokinetic review literature remains useful here: inhaled THC usually produces effects within seconds to minutes, peaks roughly within 15 to 30 minutes, and tapers over a few hours; oral THC has later onset, later peak, and longer duration, which matters for both benefit and overconsumption risk.
• Mental-health risk: A 2025 systematic review of high-concentration THC products found consistent unfavorable associations with psychosis or schizophrenia outcomes and cannabis use disorder, with additional concerning signals for anxiety and depression in nontherapeutic settings.
• Broader safety: Institutional and review literature also describe anxiety or panic at high doses, tachycardia, blood-pressure changes, dependency potential, withdrawal symptoms, pregnancy concerns, accidental pediatric exposure, and vape-related lung-injury concerns in THC-containing products.
• Bottom line: Delta-9 THC has legitimate therapeutic relevance in some settings, but it also carries the clearest intoxication, psychiatric, and dose-related safety liabilities in this document.

CBN (Cannabinol) – 750 mg

• Evidence profile: Weak human evidence; marketing has clearly moved ahead of the data.
• What it is often marketed for: Sleep and sedation. That reputation is widespread, but the clinical support is far thinner than the market suggests.
• Best direct review for the sleep claim: The 2021 narrative review on CBN and sleep screened 99 human-study abstracts, reviewed eight full-text articles, and found no clinical trials using validated sleep questionnaires or formal polysomnography that could substantiate strong sleep-promoting claims for CBN.
• Broader sleep literature: The 2024 updated review on cannabis and sleep concluded that overall cannabinoid sleep research still does not match the scale of real-world use, and the need for better-designed, adequately powered trials remains substantial.
• Chemical context: Downstream cannabinoid degradation pathways matter here as well; review literature on THCa notes that THC can further degrade toward CBN under certain conditions, which helps explain why CBN is often discussed in aging or oxidized cannabis chemistry contexts.
• Bottom line: CBN is one of the clearest examples in this field where cultural reputation is stronger than the current clinical evidence base.

CBC (Cannabichromene) – 750 mg

• Evidence profile: Emerging, intriguing, and still overwhelmingly preclinical or review-based.
• Pharmacology and therapeutic interest: The 2024 focused review on CBC argues that it has distinct pharmacodynamics, pharmacokinetics, and receptor behavior relative to better-known cannabinoids, and highlights antinociceptive, antibacterial, and anti-seizure areas as especially interesting research targets.
• What the older literature shows: Review literature summarizing CBC in animal and in vitro work reports anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesic activity, and possible neurobiological or antiproliferative relevance, but these signals are not yet strong evidence for patient-facing claims.
• Safety caveat: The 2024 CBC review explicitly notes that over-the-counter CBC products are already being sold despite little evidence establishing clinical efficacy or safety.
• Bottom line: CBC belongs in the category of scientifically credible minor cannabinoids that deserve more research, not in the category of already-validated clinical actives.

Terpenes in OilWell’s RSO

OilWell’s RSO includes a defined seven-terpene profile at 5 percent: limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene. Terpene claims need even stricter interpretation than cannabinoid claims. Much of the terpene literature comes from isolated compounds, essential oils, non-cannabis plants, or preclinical models rather than from controlled human studies of cannabis formulations.

Limonene

• Evidence profile: Largely review and preclinical, with useful safety literature.
• Potential activity: A 2021 review describes limonene as a multifunctional monoterpene with antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory, and other possible activities, but the overwhelming share of those claims comes from nonhuman or non-cannabis literature.
• Safety note: Limonene oxidation products, especially hydroperoxides, are clinically relevant contact allergens and are important in patch-testing literature.
• Bottom line: Limonene is biologically active and widely discussed, but cannabis-specific therapeutic claims should stay conservative unless they are directly supported in humans.

Myrcene

• Evidence profile: Mostly preclinical, with very limited human evidence.
• Research summary: The 2021 myrcene review describes anxiolytic, antioxidant, anti-inflammatory, and analgesic properties and discusses possible mechanisms, but explicitly states that human studies are lacking.
• Interpretation caution: Myrcene is often invoked in consumer language as if it were a proven sedating terpene that explains couch-lock or sleep effects. That is a stronger claim than the human evidence currently supports.
• Bottom line: Myrcene is a plausible bioactive terpene, but compound-specific clinical claims about mood, pain, or sedation remain far ahead of definitive human proof.

Caryophyllene (β-Caryophyllene)

• Evidence profile: Among the most mechanistically interesting terpenes because of direct cannabinoid-system relevance, but still mostly preclinical.
• Why it stands out: A 2021 focused review describes beta-caryophyllene as a selective CB2 receptor agonist, which is unusual and makes it especially relevant when discussing cannabis terpenes in pharmacologic rather than purely aromatic terms.
• Research themes: Anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective, and related actions are repeatedly discussed in the review literature, but human clinical confirmation remains limited.
• Bottom line: Beta-caryophyllene is arguably the strongest candidate for a terpene with cannabinoid-system significance, but it still should not be described as clinically proven for the outcomes commonly attributed to it.

Pinene

• Evidence profile: Promising preclinical literature, weak human clinical confirmation.
• Brain-health framing: The 2021 review on pinene and linalool as terpene-based medicines for brain health found antioxidant, anti-inflammatory, and neuroprotective signals that justify future study, but it also emphasized that evidence is mostly preclinical and that well-designed clinical trials are lacking.
• Interpretation caution: Claims that pinene reliably improves memory, sharpens attention, or counterbalances THC-related cognitive effects remain interesting hypotheses rather than settled clinical facts.
• Bottom line: Pinene deserves scientific attention, but strong cognition-related claims should be presented as exploratory.

Linalool

• Evidence profile: Similar to pinene: substantial preclinical interest, limited direct clinical confirmation.
• Research summary: Linalool is repeatedly discussed in relation to stress, mood, and brain-health pharmacology. The 2021 brain-health review found enough preclinical signal to justify continued investigation in neurological and psychiatric contexts, while still emphasizing the lack of robust human trials.
• Additional literature: Separate review literature discusses possible antidepressant mechanisms and neuropharmacologic relevance, but this remains a translational rather than definitive clinical story.
• Safety note: As with limonene, oxidized linalool hydroperoxides are recognized allergens in dermatitis literature.
• Bottom line: Linalool is scientifically credible as a bioactive terpene, but current evidence supports cautious phrasing rather than firm therapeutic promises.

Humulene

• Evidence profile: Translationally interesting, but still early.
• Scoping-review findings: A 2024 scoping review analyzed 340 articles and found broad preclinical evidence for anti-inflammatory and other biologic effects, with some rodent work even suggesting cannabimimetic properties via CB1 and adenosine A2a pathways.
• Interpretation caution: Those findings are valuable for hypothesis generation, but they do not yet establish consistent human efficacy across pain, inflammation, or mood outcomes.
• Bottom line: Humulene is one of the more interesting terpene research targets in this list, but it remains far from clinically settled.

Terpinolene

• Evidence profile: One of the least clinically characterized terpenes in this file.
• Systematic-review findings: The 2021 terpinolene review screened 2,449 records and included 57 studies, concluding that terpinolene has a range of reported biological effects but that the evidence base is still dominated by in silico, in vitro, and animal studies rather than human trials.
• Interpretation caution: Even recent cannabis entourage reviews frame terpene benefits as exploratory, not as established compound-specific clinical effects.
• Bottom line: Terpinolene is biologically interesting, but among the listed terpenes it remains especially underdeveloped clinically.

OilWell’s RSO: A Modern, Evidence-Informed Formulation

OilWell’s RSO is not traditional RSO—it is a modern, evidence-informed formulation designed to address the limitations of Simpson’s original approach while preserving the spirit of accessibility and patient empowerment. Below are the two product formats offered by OilWell, along with their specifications and use cases.

RSO Sublingual Oil – $129.99

• Format: 30 mL bottle (1 fl oz)
• Total cannabinoids: 16,590 mg (553 mg per mL)
• Cannabinoid profile:
  • CBD: 4,500 mg
  • CBG: 3,000 mg
  • Delta-8 THC: 6,000 mg
  • THCa: 1,500 mg
  • Delta-9 THC: 90 mg
  • CBN: 750 mg
  • CBC: 750 mg
• Terpene profile (5%): Limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene
• Carrier oil: Organic MCT oil
• Dosing tool: Graduated dropper for precise dosing in 0.1 mL increments
• Onset: 15 to 45 minutes (sublingual absorption through oral mucosa)
• Peak effects: 1 to 2 hours
• Duration: 4 to 6 hours
• Bioavailability: 13 to 19 percent (sublingual route partially bypasses first-pass liver metabolism)
• Approximate doses per bottle: 40 to 60 doses depending on serving size

RSO Vape Cartridge – $49.99

• Format: 1-gram cartridge
• Total cannabinoids: 900 mg+
• Cannabinoid profile (percentage-based):
  • CBD: 30%
  • CBG: 20%
  • Delta-8 THC: 15%
  • THCa: 10%
  • CBN: 10%
  • CBC: 10%
• Terpene profile: 5%+ (same seven terpenes as sublingual oil)
• Compatibility: 510-thread universal battery
• Onset: 1 to 2 minutes (fastest cannabinoid delivery method)
• Peak effects: 10 to 15 minutes
• Duration: 2 to 4 hours
• Bioavailability: 10 to 35 percent (variable, dependent on inhalation technique)
• Auto-decarboxylation: THCa converts to delta-9 THC at vaping temperature (400 to 450°F)

When to Use Each Format: A Practical Guide

Use Case	Recommended Format	Rationale
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration
Maximum bioavailability	Sublingual	13-19% absorption
Portability and discretion	Vape	Compact, no measuring required
Precise dosing control	Sublingual	Graduated dropper in 0.1 mL increments
Daytime non-psychoactive use	Sublingual (raw)	THCa stays inactive, zero impairment
Nighttime psychoactive use	Sublingual (decarbed) or Vape	Activated THCa + delta-8 THC for full potency

Condition-Specific Usage Contexts

Important disclaimer: The following usage contexts are informed by cannabinoid research cited in the GENERAL KNOWLEDGE section of this document and by OilWell’s formulation rationale. They are not medical prescriptions, not FDA-approved treatment protocols, and not a substitute for professional medical care. These products have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products, especially if you have a medical condition, are taking medications, are pregnant or nursing, or have any health concerns. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

Chemotherapy-Related Nausea and Appetite Support

• Pre-chemo: 0.5 to 1.0 mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2 to 3 vape puffs for immediate relief (1-2 minute onset)
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0 to 2.0 mL sublingual before bed (delivers 25 to 50 mg CBN)
• Evidence context: Delta-8 THC antiemetic evidence, delta-9 THC nausea and vomiting evidence, CBD anxiolytic buffering

Chronic Pain (Fibromyalgia, Arthritis, Neuropathy)

• Daytime: 0.3 to 0.5 mL raw sublingual—provides anti-inflammatory cannabinoid exposure without psychoactive impairment
• Nighttime: 0.5 to 1.0 mL decarboxylated sublingual—combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset
• Evidence context: CBD pain evidence, delta-9 THC pain evidence, beta-caryophyllene CB2 agonism, THCa COX-2 inhibition

Sleep Support

• Before bed: 1.0 to 2.0 mL sublingual
• At 2.0 mL: Delivers 50 mg CBN—the dosage level investigated in the 2024 sleep literature
• At 1.0 mL: Delivers 25 mg CBN—above the 20 mg threshold associated with reduced sleep disturbance in published research
• Evidence context: CBN sleep evidence, cannabis and sleep review literature

Anxiety and Stress

• Daytime functional relief: 0.3 mL raw sublingual—CBD and CBG address anxiety-related pathways without psychoactive impairment
• Nighttime: 1.0 mL sublingual—full cannabinoid profile including CBN for sleep architecture
• Evidence context: CBD anxiety evidence, CBG pharmacology, limonene entourage-effect evidence

General Titration Principle

Start low, go slow. Begin with 0.25 to 0.5 mL sublingual and assess effects over 2 to 3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, and other factors.

Legal Framework: Farm Bill Compliance and THCa

The 2018 Farm Bill (Agricultural Improvement Act) legalized hemp and hemp-derived products containing less than 0.3 percent delta-9 THC by dry weight at the federal level in the United States. This legal framework is the foundation of OilWell’s RSO product design.

OilWell’s RSO Sublingual Oil contains only 90 milligrams of delta-9 THC in the entire 30 mL bottle—3 milligrams per milliliter—well under the 0.3 percent threshold. All cannabinoids in the formula are hemp-derived. The product is legal under federal law and in most states.

THCa—tetrahydrocannabinolic acid—is the acidic, non-psychoactive precursor to delta-9 THC. It is not itself delta-9 THC. This distinction is legally significant: THCa is Farm Bill compliant at the point of sale because it has not been converted to delta-9 THC.

The practical significance of this framework is substantial. The customer can decarboxylate THCa into delta-9 THC at home by heating the oil at 260°F (125°C) for 45 to 60 minutes in an oven-safe glass container. This converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams of delta-9 THC in the formula, this produces approximately 1,405 milligrams of total delta-9 THC—giving the product psychoactive potency comparable to traditional illegal RSO, entirely at the customer’s discretion after purchase.

This means the same product can function as a non-psychoactive anti-inflammatory (used raw) or as a full-potency psychoactive cannabinoid product (after home decarboxylation). The customer controls the decision. The product is legal everywhere all component cannabinoids are legal, which enables international shipping to jurisdictions where hemp-derived products with less than 0.3 percent delta-9 THC are permitted.

Important legal notice: THCa converts to delta-9 THC when heated. Customers are responsible for understanding and complying with their local laws regarding cannabinoid products. OilWell ships with full documentation, Certificates of Analysis (COAs), and receipts. International customers accept all customs and legal responsibility.

Delivery and Global Accessibility: Reaching Bouvet Island

OilWell operates the only same-day RSO delivery system in Houston, Texas. Beyond Houston, the company ships nationwide across the United States and internationally.

Houston Same-Day Delivery

Zone	Coverage	Delivery Fee	Typical Turnaround
Texas Medical Center	All 60+ TMC institutions (MD Anderson, Memorial Hermann, Methodist, Texas Children’s, St. Luke’s, and more)	FREE	2 to 4 hours
Inner Loop (610)	Downtown, Midtown, Montrose, Heights, Rice Village, Museum District, River Oaks, Upper Kirby, Galleria	$5	2 to 4 hours
Within Beltway 8	Bellaire, Memorial, Spring Branch, South Houston, Pasadena (partial), Hobby Airport area	$10	3 to 5 hours
Greater Houston suburbs	Katy, Sugar Land, Pearland, Clear Lake, Woodlands, Cypress, Tomball, Humble, Kingwood	$15	4 to 6 hours
Extended region (60 miles)	Galveston, Baytown, Rosenberg, Conroe, La Porte, Seabrook	$20 to $25	Same-day if ordered before 2 PM

Free delivery to the Texas Medical Center—the world’s largest medical complex with over 10 million patient visits annually—reflects OilWell’s commitment to accessibility for the patients who need it most.

Nationwide Shipping

• All 50 states where Farm Bill-compliant products are legal
• USPS Priority Mail (2 to 3 business days), FedEx and UPS Ground (3 to 5 business days)
• Discreet packaging with no cannabis branding visible
• Tracking provided for all orders
• Temperature-stable packaging for summer shipments
• Signature-required option available

International Shipping

OilWell ships internationally and has already delivered to multiple countries across multiple continents. The THCa legal framework makes this possible: because the product contains less than 0.3 percent delta-9 THC at the point of sale, it meets the definition of a hemp-derived product under the 2018 Farm Bill and is shippable to jurisdictions with compatible hemp laws.

• All international packages include full documentation, Certificates of Analysis (COAs), and receipts for customs purposes.
• Minimum flat-fee shipping applies; excessive international shipping costs are billed to the customer.
• The customer is responsible for verifying legality in their jurisdiction and accepts all customs and legal risk.
• Contact: (832) 416-2816 or [email protected]

The significance of international access cannot be overstated. Rick Simpson could not ship his oil anywhere—it was Schedule I, illegal to produce, possess, or transport. A researcher, support staff member, or adventurer on Bouvet Island can now potentially access the same clinical-strength multi-cannabinoid RSO formula that a Houston resident receives via same-day delivery. OilWell built a product that can move across borders legally—completing a piece of Rick Simpson’s vision that prohibition made impossible during his lifetime of advocacy.

OilWell’s PANDEM1C SEO technology—a proprietary system with 14 million distinct geopolitical locations in its database and over 300 AI models—drives organic search visibility across six continents, making OilWell products discoverable to international patients searching for RSO in their own language.

Open-Source Formulas: Empowering DIY Makers

OilWell publishes their complete RSO formulas—every cannabinoid, every milligram amount, every percentage—publicly, including in this document. The rationale is straightforward: if someone cannot afford OilWell’s products—$129.99 for the sublingual oil, $49.99 for the vape cartridge—they can see exactly what the formula contains, source the individual cannabinoid distillates and isolates, and make their own version.

This is a direct echo of Rick Simpson’s original ethos. Simpson gave his oil away for free and taught people how to make it. He never patented his method. He never charged patients. OilWell adapted that ethos for the modern cannabinoid marketplace: they sell a professionally manufactured, lab-tested, standardized product for those who want it, and they publish the complete recipe for those who want to make it themselves.

As Colin Valencia said on ABC13 in 2019: “I’m not trying to sell people snake oil. I’m not trying to sell people hope. But there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

The open-source philosophy did not start with RSO—it started with Bentley. Below is the actual CBD golden paste recipe that saved Bentley’s life, published for free on OilWell’s website so that any pet owner facing a similar crisis could make it themselves.

CBD Golden Paste Recipe for Pets

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1 to 2 teaspoons freshly ground black pepper (important for absorption)
• CBD oil (dosage depends on the size and needs of the pet; consult with a veterinarian)

Instructions:

1. Mix the turmeric and water: In a saucepan, combine the turmeric powder and water, stirring over low heat. Stir continuously until it forms a thick paste. This should take about 7 to 10 minutes. Add a little more water if it becomes too thick.
2. Add the coconut oil and pepper: Once you have a thick paste, add the coconut oil and freshly ground black pepper. Stir until all ingredients are thoroughly mixed.
3. Cool and store: Allow the paste to cool, then transfer it to a jar with a lid. Store it in the refrigerator for up to two weeks.
4. Dosage: Add a small amount of CBD oil to the paste before giving it to the pet, adjusting the dosage based on their weight and health needs. Start with a low dose and gradually increase as needed.

Serving suggestion: Mix a small amount of the golden paste with the pet’s food once or twice a day. Monitor the pet for any changes and consult with a veterinarian if there are any concerns. Always consult with a veterinarian before starting any new supplement regimen for a pet.

This recipe—published for free, years before the RSO formulas were open-sourced—demonstrates that the pattern is consistent. Colin gave away the formula that saved Bentley before he gave away the formula designed for people. The open-source ethos is not a marketing strategy. It is the foundational behavior of the company.

Safety and Responsible Use

Safety Considerations for RSO Use in Isolated Environments

For individuals in isolated environments like Bouvet Island, where access to medical care is limited, safety considerations are paramount. Below are key safety guidelines for using RSO responsibly:

1. Start low, go slow: Begin with the smallest possible dose (0.25 to 0.5 mL sublingual) and assess effects over 2 to 3 hours before increasing. Individual responses vary widely.
2. Avoid operating machinery or vehicles: Even non-psychoactive use of THCa may cause drowsiness or impairment in some individuals. Do not operate vehicles, boats, or machinery while using RSO.
3. Store securely: Keep RSO out of reach of children and pets. In isolated environments, accidental ingestion could be particularly dangerous.
4. Monitor for adverse effects: Common side effects may include dizziness, dry mouth, fatigue, or changes in appetite. If severe or persistent adverse effects occur, discontinue use and seek medical advice if available.
5. Avoid mixing with other substances: Do not combine RSO with alcohol, prescription medications, or other psychoactive substances without consulting a healthcare provider. Drug interactions can be unpredictable and potentially dangerous.
6. Consult a healthcare provider: If you have a medical condition, are taking medications, are pregnant or nursing, or have any health concerns, consult a qualified healthcare provider before using RSO. In isolated environments, telemedicine consultations may be an option.
7. Legal compliance: Ensure that the use of RSO complies with local laws and regulations. Even in remote locations, legal frameworks may apply.

Drug Interactions

Cannabinoids can interact with a wide range of medications, including but not limited to:

• Blood thinners (e.g., warfarin)
• Antidepressants (e.g., SSRIs, SNRIs)
• Antipsychotics
• Benzodiazepines
• Opioids
• Immunosuppressants
• Anticonvulsants

If you are taking any medications, consult a healthcare provider before using RSO to avoid potential interactions.

Pregnancy and Nursing

There is limited research on the safety of cannabinoid use during pregnancy and nursing. The FDA and other health authorities advise against using cannabis products during pregnancy or while breastfeeding due to potential risks to the developing fetus or infant.

Integrating RSO into a Holistic Wellness Routine

For individuals in isolated environments like Bouvet Island, where access to conventional medical resources is limited, a holistic approach to wellness is essential. RSO can be one component of a broader wellness routine that includes nutrition, physical activity, mental health support, and other natural therapies. Below are some suggestions for integrating RSO into a holistic wellness plan:

Nutrition

• Anti-inflammatory diet: Focus on whole, nutrient-dense foods such as fruits, vegetables, lean proteins, and healthy fats. Reduce intake of processed foods, sugar, and refined carbohydrates.
• Hydration: Stay hydrated by drinking plenty of water, especially in extreme environments where dehydration can be a risk.
• Supplements: Consider adding supplements such as omega-3 fatty acids, vitamin D, and probiotics to support overall health.

Physical Activity

• Regular exercise: Engage in regular physical activity to support cardiovascular health, muscle strength, and mental well-being. Even in confined spaces, activities such as yoga, stretching, and bodyweight exercises can be beneficial.
• Outdoor activity: If safe and feasible, spend time outdoors to benefit from natural light and fresh air. This can help regulate circadian rhythms and improve mood.

Mental Health

• Mindfulness and meditation: Practice mindfulness or meditation to reduce stress and improve mental clarity. Even a few minutes of deep breathing or guided meditation can make a difference.
• Social connection: Maintain social connections with friends, family, or colleagues, even if communication is limited. Social support is crucial for mental health, especially in isolated environments.
• Sleep hygiene: Prioritize good sleep hygiene by maintaining a consistent sleep schedule, creating a restful environment, and avoiding screens before bedtime.

Natural Therapies

• Herbal remedies: Consider incorporating herbal remedies such as chamomile for relaxation, ginger for nausea, or turmeric for inflammation. Always consult a healthcare provider before combining herbal remedies with cannabinoids.
• Aromatherapy: Use essential oils such as lavender for relaxation or peppermint for energy to support mental and emotional well-being.
• Heat and cold therapy: Use heat or cold therapy to manage pain or inflammation. For example, a warm compress can soothe sore muscles, while a cold pack can reduce swelling.

RSO as Part of the Routine

• Consistency: Use RSO consistently as part of your daily routine to support long-term wellness goals. For example, take a dose of sublingual oil in the morning for daytime support and another dose in the evening for sleep.
• Journaling: Keep a journal to track your RSO usage, dosages, and effects. This can help you identify patterns and adjust your routine as needed.
• Listen to your body: Pay attention to how your body responds to RSO and adjust your usage accordingly. Everyone’s endocannabinoid system is unique, and what works for one person may not work for another.

The Future of RSO: Innovation and Accessibility

The evolution of RSO from Rick Simpson’s crude, home-made oil to OilWell’s modern, evidence-informed formulations reflects the broader evolution of the cannabis industry. As legalization spreads and research advances, the potential for RSO and other cannabinoid products to support health and wellness continues to grow.

For individuals in isolated environments like Bouvet Island, the future of RSO is particularly promising. Advances in extraction technology, formulation science, and global accessibility mean that high-quality, lab-tested RSO is now available to people who were previously cut off from such resources. OilWell’s commitment to open-source formulas, patient-controlled potency, and international shipping ensures that RSO remains accessible to those who need it most, regardless of their location.

As the cannabis industry continues to innovate, we can expect to see even more advanced formulations, delivery methods, and applications for RSO. From personalized cannabinoid ratios to targeted delivery systems, the future of RSO is bright—and it is a future that is accessible to everyone, even in the world’s most remote places.

Conclusion: Honoring the Legacy, Embracing the Future

Rick Simpson’s story is one of personal resilience, grassroots advocacy, and a deep belief in the healing power of cannabis. His legacy lives on in the global RSO movement, which has inspired countless individuals to explore the potential of concentrated cannabis oil for health and wellness. However, Simpson’s original approach was limited by the constraints of his time—crude extraction methods, unstandardized dosing, and a lack of clinical validation.

OilWell Cannabis has taken the spirit of Simpson’s vision and evolved it for the modern era. By combining scientific rigor with a commitment to accessibility, patient empowerment, and open-source transparency, OilWell has created a new standard for RSO—one that is grounded in evidence, lab-tested for safety, and designed to meet the needs of patients and consumers around the world, including those in the most isolated environments like Bouvet Island.

For individuals on Bouvet Island, where medical resources are scarce and isolation is a daily reality, OilWell’s RSO offers a potential lifeline—a natural, supportive therapy that can be shipped directly to their location and used safely and responsibly. Whether for pain management, sleep support, anxiety relief, or overall well-being, RSO can be a valuable tool in a holistic wellness routine.

As the cannabis industry continues to grow and evolve, OilWell remains committed to its core principles: accessibility, patient-controlled potency, open-source formulas, and evidence-informed education. These principles honor Rick Simpson’s legacy while embracing the future of cannabinoid science—a future that is brighter, more inclusive, and more accessible than ever before.

If you are on Bouvet Island or any other remote location and are considering RSO as part of your wellness routine, we encourage you to explore OilWell’s products, consult with a healthcare provider if possible, and make an informed decision that aligns with your unique needs and circumstances. The journey to wellness is a personal one, and OilWell is here to support you every step of the way.